Patrys appoints Dr Marie Roskrow as new CMO and president

Melbourne biotech Patrys has appointed renowned medical academic Dr Marie Roskrow as its Chief Medical Officer and President.

The announcement coincides with the company receiving approval for its first in-human clinical trial of its PAT-SM6 natural human antibody on melanoma patients in Australia, set to commence shortly. Dr Roskrow will also work to advance a number of other Patrys products through clinical development.

In her role as President, Dr. Roskrow brings to Patrys a depth of experience in healthcare investment banking which has seen her develop an extensive professional network within the drug development industry.

Patrys’ CEO Dan Devine said: “This appointment strengthens the capabilities of the Company in two critical areas. Firstly, Dr. Roskrow's extensive drug development experience will benefit our current clinical stage products PAT-SM6 and PAT-SC1, and the rest of our pipeline as it advances.”

“Secondly, Dr. Roskrow's international banking experience will help Patrys in refining our corporate and business development strategies."

Dr Roskrow has held a number of senior clinical and research positions. Most recently she was University Professor/ Research Group Leader in Translational Medicine at the Institute for Molecular Immunology, GSF, Munich, Germany. During this time she founded Roskrow & Partners Pty Ltd providing strategic and corporate advice to biotechnology and medical device companies in a number of countries. She has also served as a board member on two private biotechnology companies.

Dr Roskrow has a PhD (Medicine) from the University of London.